Abstract
Prostate cancer is predicted to be the most common cancer diagnosed in American men in 2006 with an estimated 230,000 new cases in the United States alone [1]. It is likely to result in over 27,000 deaths in 2006, and the average male will have a one in six chance of developing this malady in his lifetime [1]. These statistics illustrate the need to have screening and treatment systems in place that possess both a high degree of sensitivity as well as proven effectiveness. With the recent strides made in the field of molecular and cellular biology, it is now possible to analyze and tailor treatments to an individuals tumor. As the methods of analysis become more refined, researchers are better able to sift through the vast amounts of data and hone in on promising new targets. Molecular prognostic markers are already beginning to appear as a result of modern genomic analysis, and more are on the way. These markers are appearing in a variety of pathways including signal transduction, apoptosis, cell cycle regulation, angiogenesis, and cell adhesion. The emergence of viable prognostic markers indicative of specific tumor types holds the potential of greatly improving cancer screening methods as well as overall patient survival.
Keywords: Prostate cancer, biomarkers, prognosis, treatment
Current Cancer Therapy Reviews
Title: Molecular and Genetic Profiling of Prostate Cancer: Implications for Future Therapy
Volume: 3 Issue: 1
Author(s): Gregory Saia, Min Zhang, Vincent Depalo, Tim Lautenschlager and Arnab Chakravarti
Affiliation:
Keywords: Prostate cancer, biomarkers, prognosis, treatment
Abstract: Prostate cancer is predicted to be the most common cancer diagnosed in American men in 2006 with an estimated 230,000 new cases in the United States alone [1]. It is likely to result in over 27,000 deaths in 2006, and the average male will have a one in six chance of developing this malady in his lifetime [1]. These statistics illustrate the need to have screening and treatment systems in place that possess both a high degree of sensitivity as well as proven effectiveness. With the recent strides made in the field of molecular and cellular biology, it is now possible to analyze and tailor treatments to an individuals tumor. As the methods of analysis become more refined, researchers are better able to sift through the vast amounts of data and hone in on promising new targets. Molecular prognostic markers are already beginning to appear as a result of modern genomic analysis, and more are on the way. These markers are appearing in a variety of pathways including signal transduction, apoptosis, cell cycle regulation, angiogenesis, and cell adhesion. The emergence of viable prognostic markers indicative of specific tumor types holds the potential of greatly improving cancer screening methods as well as overall patient survival.
Export Options
About this article
Cite this article as:
Saia Gregory, Zhang Min, Depalo Vincent, Lautenschlager Tim and Chakravarti Arnab, Molecular and Genetic Profiling of Prostate Cancer: Implications for Future Therapy, Current Cancer Therapy Reviews 2007; 3 (1) . https://dx.doi.org/10.2174/157339407780126647
DOI https://dx.doi.org/10.2174/157339407780126647 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Functional Proteomic Approach to the Identification and Characterization of Protein Composition in Wheat Leaf
Current Proteomics Tumor-Specific Delivery of Histidine-Rich Glycoprotein Suppresses Tumor Growth and Metastasis by Anti-angiogenesis and Vessel Normalization
Current Gene Therapy PI-3 Kinase-PTEN Signaling Node: An Intercept Point for the Control of Angiogenesis
Current Pharmaceutical Design Antioxidant Therapy in Alzheimers Disease: Theory and Practice
Mini-Reviews in Medicinal Chemistry Integrins as A New Target for Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Control of Tumor Markers Using Nanotechnology
Mini-Reviews in Medicinal Chemistry Molecular Imaging in Optical Coherence Tomography
Current Molecular Imaging (Discontinued) Is Small Really Beautiful? Nanosensors and Low Abundance Biomarkers for Personalized Medicine
Current Pharmacogenomics and Personalized Medicine One-Step Synthesis of 1H-1,2,3-Triazol-1-Ylmethyl-2,3-Dihydronaphtho[1,2-b]furan- 4,5-Diones
Current Organic Synthesis The Role of STATs in Inflammation and Inflammatory Diseases
Current Pharmaceutical Design SAR, QSAR and Docking of Anticancer Flavonoids and Variants: A Review
Current Topics in Medicinal Chemistry A Review: The Anti-inflammatory, Anticancer and Antibacterial Properties of Four Kinds of Licorice Flavonoids Isolated from Licorice
Current Medicinal Chemistry Pomegranate, its Components, and Modern Deliverable Formulations as Potential Botanicals in the Prevention and Treatment of Various Cancers
Current Drug Delivery Advances in the Development of Class I Phosphoinositide 3-Kinase (PI3K) Inhibitors
Current Topics in Medicinal Chemistry Editorial {Hot topic: QSPR Models for Computer-Aided Drug Design in Microbiology, Parasitology, and Pharmacology (Guest Editor: Humberto Gonzalez-Diaz)]
Current Computer-Aided Drug Design Innovations and Opportunities to Improve Conventional (Deoxy)Nucleoside and Fluoropyrimidine Analogs in Cancer
Current Medicinal Chemistry Estrogen-Related Receptors as Emerging Targets in Cancer and Metabolic Disorders
Current Topics in Medicinal Chemistry Functional Nanoplatforms for Enhancement of Chemotherapeutic Index
Anti-Cancer Agents in Medicinal Chemistry Disintegrin Tablysin-15 Suppresses Cancer Hallmarks in Melanoma Cells by Blocking FAK/Akt/ERK and NF-κB Signaling
Current Cancer Drug Targets Gene Therapy in Liver Diseases: State-of-the-Art and Future Perspectives
Current Gene Therapy